Fox Chase Cancer Center

 

19th Annual Highlights of the 2020 San Antonio Breast Cancer Symposium
06:39

Fox Chase Cancer Center

SABCS Highlights on HR+ HER2- mBC: The All-Oral Regimen of Tesetaxel+Reduced Dose of Cape, Survival Data With Exemestane + Entinostat in AI-Resistant Disease

FEATURING Jennifer Matro
  • 126 views
  • April 13, 2021
17:32

Fox Chase Cancer Center

SABCS Takeaways on HR+ eBC: Neoadjuvant Weekly Nab-Paclitaxel vs. Dose Dense Paclitaxel, ET Alone in Intermediate / High-Risk Luminal Disease, NCT in Postmenopausal Women Resistant to ET

FEATURING Jennifer Matro
  • 109 views
  • April 13, 2021
17:29

Fox Chase Cancer Center

SABCS Update on HER2+ EBC: Extended Adjuvant Neratinib, T-DM1 vs. TH, T-DM1 PFS vs. Trastuzumab, Optimal Duration of Trastuzumab, DFS With Adjuvant Pertuzumab in LN+ Disease

FEATURING Lori Goldstein
  • 37 views
  • April 13, 2021
13:04

Fox Chase Cancer Center

SABCS Update on HER2+ MBC: Tucatinib vs. Placebo, T-DXd, Margetuximab + CTX vs. H + CTX, Pyrotinib

FEATURING Lori Goldstein
  • 41 views
  • April 13, 2021
23:31

Fox Chase Cancer Center

Fox Chase SABCS Highlights on Local Control and Ductal Carcinoma In Situ: Radioactive I Seed Placement in the Axilla, 12 yrs of Anastrozole vs. Tam, XRT in 65+ y/o Women, XRT Doses & Fractionation

FEATURING Richard Bleicher
  • 20 views
  • April 13, 2021